BMEA logo

Biomea Fusion, Inc.

BMEA
Healthcare|Biotechnology|US
$0.57
-0.02 (-3.51%)
DCF Value
$0.98
Tangible Book / Share
$0.17
Cash / Share
$0.48
Next Earnings Report
Mar 30, 2027
EPS est. -$0.29
Financing Filings (last 12 months)
1
Shelf registrations / offering prospectuses — latest Sep 22, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (2)

Mar 2027
Est. completion
P2Type 2 Diabetes
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets
NCT07502495n=64
Jun 2027
Est. completion
P2Type 2 Diabetes
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy
NCT07502508n=60

Recent Press Releases

Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist
Oct 13, 2026 · GlobeNewsWire
Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist
Oct 12, 2026 · GlobeNewsWire
Biomea Fusion Announces Termination of Proposed Public Offering of Securities
Sep 23, 2026 · GlobeNewsWire
Biomea Fusion Announces Proposed Public Offering of Securities
Sep 22, 2026 · GlobeNewsWire
Biomea Fusion to Participate in Upcoming Investor Conferences
Sep 3, 2026 · GlobeNewsWire
Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes
Aug 24, 2026 · GlobeNewsWire
Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity
Aug 13, 2026 · GlobeNewsWire

SEC Filings (60)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 14, 20268-KMaterial eventDocumentIndex
Sep 22, 2026424B5Offering prospectusDocumentIndex
Sep 22, 20268-KMaterial eventDocumentIndex
Aug 5, 202610-QQuarterly reportDocumentIndex
Aug 5, 20268-KMaterial eventDocumentIndex
Jun 11, 20268-KMaterial eventDocumentIndex
May 11, 202610-QQuarterly reportDocumentIndex
May 11, 20268-KMaterial eventDocumentIndex
Apr 28, 20268-KMaterial eventDocumentIndex
Apr 27, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 27, 2026ARSAnnual report to holdersDocumentIndex
Mar 24, 202610-KAnnual reportDocumentIndex
Mar 24, 20268-KMaterial eventDocumentIndex
Feb 25, 20268-KMaterial eventDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 12, 2026SC 13GPassive 5%+ stakeDocumentIndex
Feb 6, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jan 14, 20268-KMaterial eventDocumentIndex
Jan 6, 2026S-8Employee stock planDocumentIndex
Dec 8, 2025SC 13GPassive 5%+ stakeDocumentIndex
Nov 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 7, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 4, 202510-QQuarterly reportDocumentIndex
Nov 4, 20258-KMaterial eventDocumentIndex
Oct 24, 2025SC 13D/AActivist / 5%+ stakeDocumentIndex
Oct 10, 2025SC 13D/AActivist / 5%+ stakeDocumentIndex
Oct 7, 20258-KMaterial eventDocumentIndex
Oct 7, 2025424B5Offering prospectusDocumentIndex
Oct 6, 2025424B5Offering prospectusDocumentIndex
Oct 6, 20258-KMaterial eventDocumentIndex
Aug 15, 2025EFFECTDocumentIndex
Aug 13, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Aug 11, 2025SC 13GPassive 5%+ stakeDocumentIndex
Aug 5, 2025S-3Shelf registrationDocumentIndex
Aug 5, 202510-QQuarterly reportDocumentIndex
Aug 5, 20258-KMaterial eventDocumentIndex
Jul 24, 20258-KMaterial eventDocumentIndex
Jul 22, 2025SC 13D/AActivist / 5%+ stakeDocumentIndex
Jul 16, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Jun 25, 2025SC 13GPassive 5%+ stakeDocumentIndex